<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:03:34 -0700</creation_date>
  <update_date>2013-01-15 19:03:34 -0700</update_date>
  <accession>HMDBP02209</accession>
  <secondary_accessions>
    <accession>7694</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>Nuclear receptor subfamily 1 group C member 1</synonym>
    <synonym>PPAR-alpha</synonym>
  </synonyms>
  <gene_name>PPARA</gene_name>
  <general_function>Involved in DNA binding</general_function>
  <specific_function>Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl- 2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the acyl-CoA oxidase gene</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB05007</accession>
      <name>Simvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05006</accession>
      <name>Atorvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01338</accession>
      <name>Palmityl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06497</accession>
      <name>Heptadecanoyl CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01114</accession>
      <name>Stearoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04258</accession>
      <name>Eicosanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01206</accession>
      <name>Acetyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01275</accession>
      <name>Propionyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01088</accession>
      <name>Butyryl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13037</accession>
      <name>Pentanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12969</accession>
      <name>Heptanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01070</accession>
      <name>Octanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13028</accession>
      <name>Nonanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06404</accession>
      <name>Decanoyl-CoA (n-C10:0CoA)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13114</accession>
      <name>Undecanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03571</accession>
      <name>Lauroyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06526</accession>
      <name>Tetracosanoyl-CoA  </name>
    </metabolite>
    <metabolite>
      <accession>HMDB02009</accession>
      <name>Crotonoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01290</accession>
      <name>Glutaconyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03944</accession>
      <name>trans-2-Hexenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03949</accession>
      <name>(2E)-Octenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03948</accession>
      <name>(2E)-Decenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03946</accession>
      <name>(2E)-Tetradecenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04257</accession>
      <name>3Z-dodecenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03712</accession>
      <name>(2E)-Dodecenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01243</accession>
      <name>Isobutyryl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11660</accession>
      <name>2-Methylhexanoyl-CoA </name>
    </metabolite>
    <metabolite>
      <accession>HMDB01113</accession>
      <name>Isovaleryl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02057</accession>
      <name>Pristanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01041</accession>
      <name>2-Methylbutyryl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02307</accession>
      <name>Acrylyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03945</accession>
      <name>(2E)-Hexadecenoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06529</accession>
      <name>trans-Octadec-2-enoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02845</accession>
      <name>Hexanoyl-CoA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14774</accession>
      <name>Clofibrate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15173</accession>
      <name>Fenofibrate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15371</accession>
      <name>Gemfibrozil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15465</accession>
      <name>Bezafibrate</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>sequence-specific dna binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>zinc ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>steroid hormone receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>sequence-specific dna binding transcription factor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ligand-dependent nuclear receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleic acid binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>dna binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>biological regulation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of biological process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of macromolecule metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of gene expression</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of transcription</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of transcription, dna-dependent</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane-bounded organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intracellular membrane-bounded organelle</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>nucleus</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Nucleus</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:2</chromosome_location>
    <locus>22q12-q13.1|22q13.31</locus>
    <gene_sequence>&gt;1407 bp
ATGGTGGACACGGAAAGCCCACTCTGCCCCCTCTCCCCACTCGAGGCCGGCGATCTAGAG
AGCCCGTTATCTGAAGAGTTCCTGCAAGAAATGGGAAACATCCAAGAGATTTCGCAATCC
ATCGGCGAGGATAGTTCTGGAAGCTTTGGCTTTACGGAATACCAGTATTTAGGAAGCTGT
CCTGGCTCAGATGGCTCGGTCATCACGGACACGCTTTCACCAGCTTCGAGCCCCTCCTCG
GTGACTTATCCTGTGGTCCCCGGCAGCGTGGACGAGTCTCCCAGTGGAGCATTGAACATC
GAATGTAGAATCTGCGGGGACAAGGCCTCAGGCTATCATTACGGAGTCCACGCGTGTGAA
GGCTGCAAGGGCTTCTTTCGGCGAACGATTCGACTCAAGCTGGTGTATGACAAGTGCGAC
CGCAGCTGCAAGATCCAGAAAAAGAACAGAAACAAATGCCAGTATTGTCGATTTCACAAG
TGCCTTTCTGTCGGGATGTCACACAACGCGATTCGTTTTGGACGAATGCCAAGATCTGAG
AAAGCAAAACTGAAAGCAGAAATTCTTACCTGTGAACATGACATAGAAGATTCTGAAACT
GCAGATCTCAAATCTCTGGCCAAGAGAATCTACGAGGCCTACTTGAAGAACTTCAACATG
AACAAGGTCAAAGCCCGGGTCATCCTCTCAGGAAAGGCCAGTAACAATCCACCTTTTGTC
ATACATGATATGGAGACACTGTGTATGGCTGAGAAGACGCTGGTGGCCAAGCTGGTGGCC
AATGGCATCCAGAACAAGGAGGCGGAGGTCCGCATCTTTCACTGCTGCCAGTGCACGTCA
GTGGAGACCGTCACGGAGCTCACGGAATTCGCCAAGGCCATCCCAGGCTTCGCAAACTTG
GACCTGAACGATCAAGTGACATTGCTAAAATACGGAGTTTATGAGGCCATATTCGCCATG
CTGTCTTCTGTGATGAACAAAGACGGGATGCTGGTAGCGTATGGAAATGGGTTTATAACT
CGTGAATTCCTAAAAAGCCTAAGGAAACCGTTCTGTGATATCATGGAACCCAAGTTTGAT
TTTGCCATGAAGTTCAATGCACTGGAACTGGATGACAGTGATATCTCCCTTTTTGTGGCT
GCTATCATTTGCTGTGGAGATCGTCCTGGCCTTCTAAACGTAGGACACATTGAAAAAATG
CAGGAGGGTATTGTACATGTGCTCAGACTCCACCTGCAGAGCAACCACCCGGACGATATC
TTTCTCTTCCCCAAACTTCTTCAAAAAATGGCAGACCTCCGGCAGCTGGTGACGGAGCAT
GCGCAGCTGGTGCAGATCATCAAGAAGACGGAGTCGGATGCTGCGCTGCACCCGCTACTG
CAGGAGATCTACAGGGACATGTACTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>468</residue_number>
    <molecular_weight>52224.6</molecular_weight>
    <theoretical_pi>6.2</theoretical_pi>
    <pfams>
      <pfam>
        <name>Hormone_recep</name>
        <pfam_id>PF00104</pfam_id>
      </pfam>
      <pfam>
        <name>zf-C4</name>
        <pfam_id>PF00105</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>None</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Peroxisome proliferator-activated receptor alpha
MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSC
PGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACE
GCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSE
KAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFV
IHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANL
DLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFD
FAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDI
FLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY</protein_sequence>
  </protein_properties>
  <genbank_protein_id>216409688</genbank_protein_id>
  <uniprot_id>Q07869</uniprot_id>
  <uniprot_name>PPARA_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1K7L</pdb_id>
  </pdb_ids>
  <genbank_gene_id>AB307690</genbank_gene_id>
  <genecard_id>PPARA</genecard_id>
  <geneatlas_id>PPARA</geneatlas_id>
  <hgnc_id>HGNC:9232</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Sher T, Yi HF, McBride OW, Gonzalez FJ: cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry. 1993 Jun 1;32(21):5598-604.</reference_text>
      <pubmed_id>7684926</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mukherjee R, Jow L, Noonan D, McDonnell DP: Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol. 1994 Nov;51(3-4):157-66.</reference_text>
      <pubmed_id>7981125</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tugwood JD, Aldridge TC, Lambe KG, Macdonald N, Woodyatt NJ: Peroxisome proliferator-activated receptors: structures and function.  Ann N Y Acad Sci. 1996 Dec 27;804:252-65.</reference_text>
      <pubmed_id>8993548</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kobayashi T, Kodani Y, Nozawa A, Endo Y, Sawasaki T: DNA-binding profiling of human hormone nuclear receptors via fluorescence correlation spectroscopy in a cell-free system. FEBS Lett. 2008 Aug 6;582(18):2737-44. Epub 2008 Jul 11.</reference_text>
      <pubmed_id>18619963</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cho MC, Lee S, Choi HS, Yang Y, Tae Hong J, Kim SJ, Yoon DY: Optimization of an enzyme-linked immunosorbent assay to screen ligand of Peroxisome proliferator-activated receptor alpha. Immunopharmacol Immunotoxicol. 2009;31(3):459-67.</reference_text>
      <pubmed_id>19263263</pubmed_id>
    </reference>
    <reference>
      <reference_text>Collins JE, Wright CL, Edwards CA, Davis MP, Grinham JA, Cole CG, Goward ME, Aguado B, Mallya M, Mokrab Y, Huckle EJ, Beare DM, Dunham I: A genome annotation-driven approach to cloning the human ORFeome.  Genome Biol. 2004;5(10):R84. Epub 2004 Sep 30.</reference_text>
      <pubmed_id>15461802</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22.  Nature. 1999 Dec 2;402(6761):489-95.</reference_text>
      <pubmed_id>10591208</pubmed_id>
    </reference>
    <reference>
      <reference_text>Li H, Gomes PJ, Chen JD: RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8479-84.</reference_text>
      <pubmed_id>9238002</pubmed_id>
    </reference>
    <reference>
      <reference_text>Caira F, Antonson P, Pelto-Huikko M, Treuter E, Gustafsson JA: Cloning and characterization of RAP250, a novel nuclear receptor coactivator. J Biol Chem. 2000 Feb 25;275(8):5308-17.</reference_text>
      <pubmed_id>10681503</pubmed_id>
    </reference>
    <reference>
      <reference_text>Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 2003 Sep 4;425(6953):90-3.</reference_text>
      <pubmed_id>12955147</pubmed_id>
    </reference>
    <reference>
      <reference_text>Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM: Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13919-24. Epub 2001 Nov 6.</reference_text>
      <pubmed_id>11698662</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, Lindstedt EL, Bamberg K: Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure. 2001 Aug;9(8):699-706.</reference_text>
      <pubmed_id>11587644</pubmed_id>
    </reference>
    <reference>
      <reference_text>Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, McKee DD, Galardi CM, Plunket KD, Nolte RT, Parks DJ, Moore JT, Kliewer SA, Willson TM, Stimmel JB: Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature. 2002 Feb 14;415(6873):813-7.</reference_text>
      <pubmed_id>11845213</pubmed_id>
    </reference>
    <reference>
      <reference_text>Oon Han H, Kim SH, Kim KH, Hur GC, Joo Yim H, Chung HK, Ho Woo S, Dong Koo K, Lee CS, Sung Koh J, Kim GT: Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists. Bioorg Med Chem Lett. 2007 Feb 15;17(4):937-41. Epub 2006 Nov 18.</reference_text>
      <pubmed_id>17157019</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sierra ML, Beneton V, Boullay AB, Boyer T, Brewster AG, Donche F, Forest MC, Fouchet MH, Gellibert FJ, Grillot DA, Lambert MH, Laroze A, Le Grumelec C, Linget JM, Montana VG, Nguyen VL, Nicodeme E, Patel V, Penfornis A, Pineau O, Pohin D, Potvain F, Poulain G, Ruault CB, Saunders M, Toum J, Xu HE, Xu RX, Pianetti PM: Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem. 2007 Feb 22;50(4):685-95. Epub 2007 Jan 23.</reference_text>
      <pubmed_id>17243659</pubmed_id>
    </reference>
    <reference>
      <reference_text>Oyama T, Toyota K, Waku T, Hirakawa Y, Nagasawa N, Kasuga JI, Hashimoto Y, Miyachi H, Morikawa K: Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures. Acta Crystallogr D Biol Crystallogr. 2009 Aug;65(Pt 8):786-95. Epub 2009       Jul 10.</reference_text>
      <pubmed_id>19622862</pubmed_id>
    </reference>
    <reference>
      <reference_text>Benardeau A, Benz J, Binggeli A, Blum D, Boehringer M, Grether U, Hilpert H, Kuhn B, Marki HP, Meyer M, Puntener K, Raab S, Ruf A, Schlatter D, Mohr P: Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorg Med Chem Lett. 2009 May 1;19(9):2468-73. Epub 2009 Mar 14.</reference_text>
      <pubmed_id>19349176</pubmed_id>
    </reference>
    <reference>
      <reference_text>Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, Habets G, West BL, Zhang KY, Milburn MV, Vlasuk GP, Hirth KP, Nolop K, Bollag G, Ibrahim PN, Tobin JF: Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. Epub 2008 Dec 30.</reference_text>
      <pubmed_id>19116277</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Clofibrate</name>
        <accession>HMDB14774</accession>
      </metabolite>
      <reference>
        <reference_text>Barclay TB, Peters JM, Sewer MB, Ferrari L, Gonzalez FJ, Morgan ET: Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent. J Pharmacol Exp Ther. 1999 Sep;290(3):1250-7.</reference_text>
        <pubmed_id>10454501</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofibrate</name>
        <accession>HMDB14774</accession>
      </metabolite>
      <reference>
        <reference_text>Murata M, Kaji H, Takahashi Y, Iida K, Mizuno I, Okimura Y, Abe H, Chihara K: Stimulation by eicosapentaenoic acids of leptin mRNA expression and its secretion in mouse 3T3-L1 adipocytes in vitro. Biochem Biophys Res Commun. 2000 Apr 13;270(2):343-8.</reference_text>
        <pubmed_id>10753628</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofibrate</name>
        <accession>HMDB14774</accession>
      </metabolite>
      <reference>
        <reference_text>Hunt MC, Lindquist PJ, Peters JM, Gonzalez FJ, Diczfalusy U, Alexson SE: Involvement of the peroxisome proliferator-activated receptor alpha in regulating long-chain acyl-CoA thioesterases. J Lipid Res. 2000 May;41(5):814-23.</reference_text>
        <pubmed_id>10787442</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofibrate</name>
        <accession>HMDB14774</accession>
      </metabolite>
      <reference>
        <reference_text>Casas F, Domenjoud L, Rochard P, Hatier R, Rodier A, Daury L, Bianchi A, Kremarik-Bouillaud P, Becuwe P, Keller J, Schohn H, Wrutniak-Cabello C, Cabello G, Dauca M: A 45 kDa protein related to PPARgamma2, induced by peroxisome proliferators, is located in the mitochondrial matrix. FEBS Lett. 2000 Jul 28;478(1-2):4-8.</reference_text>
        <pubmed_id>10922459</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofibrate</name>
        <accession>HMDB14774</accession>
      </metabolite>
      <reference>
        <reference_text>Komuves LG, Hanley K, Lefebvre AM, Man MQ, Ng DC, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR: Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo.  J Invest Dermatol. 2000 Sep;115(3):353-60.</reference_text>
        <pubmed_id>10951268</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofibrate</name>
        <accession>HMDB14774</accession>
      </metabolite>
      <reference>
        <reference_text>Gelosa P, Banfi C, Gianella A, Brioschi M, Pignieri A, Nobili E, Castiglioni L, Cimino M, Tremoli E, Sironi L: Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats. J Pharmacol Exp Ther. 2010 Nov;335(2):324-31. Epub 2010 Jul 29.</reference_text>
        <pubmed_id>20671072</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofibrate</name>
        <accession>HMDB14774</accession>
      </metabolite>
      <reference>
        <reference_text>Palkar PS, Anderson CR, Ferry CH, Gonzalez FJ, Peters JM: Effect of prenatal peroxisome proliferator-activated receptor alpha (PPARalpha) agonism on postnatal development. Toxicology. 2010 Sep 30;276(1):79-84. Epub 2010 Jul 15.</reference_text>
        <pubmed_id>20637823</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenofibrate</name>
        <accession>HMDB15173</accession>
      </metabolite>
      <reference>
        <reference_text>Clavey V, Copin C, Mariotte MC, Bauge E, Chinetti G, Fruchart J, Fruchart JC, Dallongeville J, Staels B: Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem. 1999;9(3):139-49.</reference_text>
        <pubmed_id>10494028</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenofibrate</name>
        <accession>HMDB15173</accession>
      </metabolite>
      <reference>
        <reference_text>Chaput E, Saladin R, Silvestre M, Edgar AD: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000 May 10;271(2):445-50.</reference_text>
        <pubmed_id>10799317</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenofibrate</name>
        <accession>HMDB15173</accession>
      </metabolite>
      <reference>
        <reference_text>Casas F, Pineau T, Rochard P, Rodier A, Daury L, Dauca M, Cabello G, Wrutniak-Cabello C: New molecular aspects of regulation of mitochondrial activity by fenofibrate and fasting. FEBS Lett. 2000 Sep 29;482(1-2):71-4.</reference_text>
        <pubmed_id>11018525</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenofibrate</name>
        <accession>HMDB15173</accession>
      </metabolite>
      <reference>
        <reference_text>Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart JC, Staels B, Lagrost L, Luc G: Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem. 2001 Jul 13;276(28):25841-7. Epub 2001 May 7.</reference_text>
        <pubmed_id>11342537</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenofibrate</name>
        <accession>HMDB15173</accession>
      </metabolite>
      <reference>
        <reference_text>Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, Paterniti JR Jr: Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism. 2001 Aug;50(8):963-71.</reference_text>
        <pubmed_id>11474486</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenofibrate</name>
        <accession>HMDB15173</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenofibrate</name>
        <accession>HMDB15173</accession>
      </metabolite>
      <reference>
        <reference_text>Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.</reference_text>
        <pubmed_id>10828060</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemfibrozil</name>
        <accession>HMDB15371</accession>
      </metabolite>
      <reference>
        <reference_text>Clavey V, Copin C, Mariotte MC, Bauge E, Chinetti G, Fruchart J, Fruchart JC, Dallongeville J, Staels B: Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem. 1999;9(3):139-49.</reference_text>
        <pubmed_id>10494028</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemfibrozil</name>
        <accession>HMDB15371</accession>
      </metabolite>
      <reference>
        <reference_text>Bosse Y, Pascot A, Dumont M, Brochu M, Prud'homme D, Bergeron J, Despres JP, Vohl MC: Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genet Med. 2002 Jul-Aug;4(4):311-5.</reference_text>
        <pubmed_id>12172398</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemfibrozil</name>
        <accession>HMDB15371</accession>
      </metabolite>
      <reference>
        <reference_text>Pahan K, Jana M, Liu X, Taylor BS, Wood C, Fischer SM: Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002 Nov 29;277(48):45984-91. Epub 2002 Sep 18.</reference_text>
        <pubmed_id>12244038</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemfibrozil</name>
        <accession>HMDB15371</accession>
      </metabolite>
      <reference>
        <reference_text>Shoji Y, Sanekata A, Sato M, Imaizumi K: Preparation of antiserum against rat delta6-desaturase and its use to evaluate the desaturase protein levels in rats treated with gemfibrozil, a ligand for peroxisome proliferator-activated receptor alpha. Biosci Biotechnol Biochem. 2003 May;67(5):1177-8.</reference_text>
        <pubmed_id>12834305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemfibrozil</name>
        <accession>HMDB15371</accession>
      </metabolite>
      <reference>
        <reference_text>Rizvi F, Iftikhar M, George JP: Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats. J Med Food. 2003 Summer;6(2):123-8.</reference_text>
        <pubmed_id>12935323</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Pedraza N, Solanes G, Carmona MC, Iglesias R, Vinas O, Mampel T, Vazquez M, Giralt M, Villarroya F: Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene. Diabetes. 2000 Jul;49(7):1224-30.</reference_text>
        <pubmed_id>10909982</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Cabrero A, Alegret M, Sanchez R, Adzet T, Laguna JC, Vazquez M: Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes. Arch Biochem Biophys. 2000 Aug 15;380(2):353-9.</reference_text>
        <pubmed_id>10933891</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, Komoda T, Katayama S: The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001 Jan;50(1):3-11.</reference_text>
        <pubmed_id>11172467</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Guan Y, Breyer MD: Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001 Jul;60(1):14-30.</reference_text>
        <pubmed_id>11422732</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Bonilla S, Redonnet A, Noel-Suberville C, Groubet R, Pallet V, Higueret P: Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver. J Physiol Biochem. 2001 Mar;57(1):1-8.</reference_text>
        <pubmed_id>11519881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Goldenberg I, Benderly M, Goldbourt U: Update on the use of fibrates: focus on bezafibrate.  Vasc Health Risk Manag. 2008;4(1):131-41.</reference_text>
        <pubmed_id>18629356</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Fruchart JC, Duriez P: Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006 Jan;42(1):39-64.</reference_text>
        <pubmed_id>16511610</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
